Organisation Strategy for
Denmark’s engagement with
International Partnership for Microbicides (IPM)
2014-2018
The work of IPM
IPM is leading partner in the global
HIV/AIDS response with a special focus
on women. It is a non-profit product
development partnership (PDP) with a
mission to provide safe, affordable and
effective microbicide-based HIV prevention
technologies which can be controlled by
women. Microbicides are medicines being
developed based on antiretroviral drugs
already used successfully to
treat
AIDS, but
now used to offer
protection
against HIV.
PDPs are non-profit product development
partnerships which generate resources and
forge partnerships across public, private and
philanthropic
sectors
to
accelerate
development of new health technologies.
Denmark supports IPM because
IPM offers novel solutions to address
the sexual and reproductive health and
rights of women and girls.
IPM’s work can improve maternal and
child health, reduce gender based
violence and reduce HIV infection.
Key challenges for IPM
Attracting sufficient funding as research
requires long term funding and
outcomes are not certain.
Ability to meet the expected demand for
the products upon scientific approval.
Denmark will expect IPM to
Focus on technologies relevant and
accessible to the most vulnerable and
marginalised population groups.
Ensure availability as quickly as possible
and at the lowest possible cost.
Denmark will follow-up by
Monitoring Danish priority areas based
on IPM’s own framework
Participating in annual donor
consultations.
Established
HQ
Field offices
Human
resources
CEO
Financial
resources
Denmark’s
contribution
IPM
2002
Silver Spring, MD,
USA
7 research centre
partners in 2
countries
71
Dr Zeda Rosenberg
32 mill. USD (2013)
5 mill. DKK annually
Donors (2014)
BMGF: Bill & Melinda Gates Foundation